These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 11906348)
41. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity. Kruse R; Ruzicka T; Grewe M Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152 [TBL] [Abstract][Full Text] [Related]
43. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding. Lanas A N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12802035 [No Abstract] [Full Text] [Related]
44. Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events? Bing RJ Curr Atheroscler Rep; 2003 Mar; 5(2):114-7. PubMed ID: 12573196 [TBL] [Abstract][Full Text] [Related]
45. Potential role of the new specific COX-2 inhibitors in dermatologic surgery. Weisberg NK; Becker D Dermatol Surg; 2000 Jun; 26(6):551-3. PubMed ID: 10848936 [No Abstract] [Full Text] [Related]
46. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs]. Houben JJ; Liem B Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2338. PubMed ID: 10589225 [No Abstract] [Full Text] [Related]
47. Efficacy and safety of diclofenac-cholestyramine and celecoxib in osteoarthritis. Suárez-Otero R; Robles-San Román M; Jaimes-Hernández J; Oropeza-De La Madrid E; Medina-Peñaloza RM; Rosas-Ramos R; Castañeda-Hernández G Proc West Pharmacol Soc; 2002; 45():26-8. PubMed ID: 12434517 [No Abstract] [Full Text] [Related]
50. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Dubois RN Cancer Prev Res (Phila); 2009 Apr; 2(4):285-7. PubMed ID: 19336723 [No Abstract] [Full Text] [Related]
51. [Celecoxib and the CLASS study--worse and worse...]. Slørdal L Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2219. PubMed ID: 12426903 [No Abstract] [Full Text] [Related]
52. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111 [TBL] [Abstract][Full Text] [Related]
54. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. Gyllfors P; Bochenek G; Overholt J; Drupka D; Kumlin M; Sheller J; Nizankowska E; Isakson PC; Mejza F; Lefkowith JB; Dahlén SE; Szczeklik A; Murray JJ; Dahlén B J Allergy Clin Immunol; 2003 May; 111(5):1116-21. PubMed ID: 12743579 [TBL] [Abstract][Full Text] [Related]
55. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone. Wyplosz B; Vautier S; Lillo-Le Louët A; Capron L Br J Clin Pharmacol; 2006 Apr; 61(4):474. PubMed ID: 16542210 [No Abstract] [Full Text] [Related]
56. [Gastroduodenal tolerance of celecoxib (celebrex) in patients with osteoarthrosis: an endoscopic evaluation]. Karateev AE Ter Arkh; 2001; 73(5):63-4. PubMed ID: 11517755 [No Abstract] [Full Text] [Related]
57. [Celecoxib and the CLASS study--a statement]. Wibe E; Maehlum S Tidsskr Nor Laegeforen; 2002 Sep; 122(22):2218. PubMed ID: 12426902 [No Abstract] [Full Text] [Related]
58. Anaphylaxis to celecoxib. Levy MB; Fink JN Ann Allergy Asthma Immunol; 2001 Jul; 87(1):72-3. PubMed ID: 11476468 [TBL] [Abstract][Full Text] [Related]
59. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003 [TBL] [Abstract][Full Text] [Related]